scispace - formally typeset
N

Neda Slade

Researcher at Stony Brook University

Publications -  47
Citations -  2333

Neda Slade is an academic researcher from Stony Brook University. The author has contributed to research in topics: Carcinogenesis & Cancer. The author has an hindex of 15, co-authored 45 publications receiving 2149 citations. Previous affiliations of Neda Slade include University of Zagreb.

Papers
More filters
Journal ArticleDOI

Aristolochic acid and the etiology of endemic (Balkan) nephropathy

TL;DR: The experiments test the hypothesis that chronic dietary poisoning by aristolochic acid is responsible for EN and its associated urothelial cancer and conclude that dietary exposure to AA is a significant risk factor for ENand its attendant transitional cell cancer.
Journal Article

p63 and p73: roles in development and tumor formation.

TL;DR: The tumor suppressor p53 is critically important in the cellular damage response and is the founding member of a family of proteins as discussed by the authors, which regulate cell cycle and apoptosis after DNA damage, and despite a remarkable structural and partly functional similarity among p53, mouse knockout studies revealed an unexpected functional diversity among them.
Journal ArticleDOI

ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors

TL;DR: Deregulated expression of ΔNp73 can bestow oncogenic activity upon the TP73 gene by functionally inactivating the suppressor action of p53 and TAp73 via a dominant-negative family network.
Journal ArticleDOI

Transdominant ΔTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo

TL;DR: It is found that the set of NH2-terminal p73 isoforms distinguishes ovarian cancer patients from healthy controls and thus is a molecular marker for this diagnosis, and strongly supports the hypothesis that overexpression of transdominant p 73 isoforms can function as epigenetic inhibitors of p53 in vivo, thereby alleviating selection pressure for p53 mutations in tumors.